Rapid human immunodeficiency virus disease progression is associated with human leukocyte antigen-B homozygocity and human leukocyte antigen-B51 in a cohort from Manitoba, Canada

References

• Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41:1053–6.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27:406–16.
   PubMed Web of Science ®Google Scholar
• Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008;8:619–30.
   PubMed Web of Science ®Google Scholar
• Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001;412: 334–8.
   PubMed Web of Science ®Google Scholar
• Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103–10.
   PubMed Web of Science ®Google Scholar
• Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650–5.
   PubMed Web of Science ®Google Scholar
• Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405–11.
   PubMed Web of Science ®Google Scholar
• Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283:1748–52.
   PubMed Web of Science ®Google Scholar
• Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006; 3:e403.
   Google Scholar
• Thobakgale CF, Streeck H, Mkhwanazi N, Mncube Z, Maphumulo L, Chonco F, et al. CD8(+) T cell polyfunctionality profiles in progressive and nonprogressive pediatric HIV type 1 infection. AIDS Res Hum Retroviruses 2011;27: 1005–12.
   PubMedGoogle Scholar
• International HIVCS, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551–7.
   PubMedGoogle Scholar
• Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000;97:2709–14.
   PubMed Web of Science ®Google Scholar
• Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004;432:769–75.
   PubMed Web of Science ®Google Scholar
• O’Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004;36:565–74.
   PubMed Web of Science ®Google Scholar
• Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003;54:535–51.
   PubMed Web of Science ®Google Scholar
• Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999;93:936–41.
   PubMed Web of Science ®Google Scholar
• Casado C, Colombo S, Rauch A, Martinez R, Gunthard HF, Garcia S, et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010;5: e11079.
   Google Scholar
• Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007;195:1177–80.
   PubMed Web of Science ®Google Scholar
• Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002;185:1244–50.
   PubMed Web of Science ®Google Scholar
• Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197:707–13.
   PubMed Web of Science ®Google Scholar
• Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007;45:28–33.
   PubMed Web of Science ®Google Scholar
• Croitoru-Lamoury J, Guillemin GJ, Boussin FD, Mognetti B, Gigout LI, Cheret A, et al. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia 2003;41:354–70.
   PubMed Web of Science ®Google Scholar
• Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, Wainberg MA. Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology 2010;7:44.
   PubMed Web of Science ®Google Scholar
• Lin YL, Mettling C, Portales P, Rouzier R, Clot J, Reynes J, et al. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 2008;22:430–2.
   PubMedGoogle Scholar
• Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, et al. HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol 2009;83:1228–39.
   PubMedGoogle Scholar
• Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001;344:1668–75.
   PubMed Web of Science ®Google Scholar
• Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS 1993;7:497–500.
   PubMedGoogle Scholar
• Klein MR, Keet IP, D’Amaro J, Bende RJ, Hekman A, Mesman B, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994;169:1244–9.
   PubMedGoogle Scholar
• Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992;5:37–45.
   PubMed Web of Science ®Google Scholar
• Scorza Smeraldi R, Fabio G, Lazzarin A, Eisera N, Uberti Foppa C, Moroni M, et al. HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts. Hum Immunol 1988; 22:73–9.
   PubMedGoogle Scholar
• Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, Martin MP, et al. HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med 2009;206:2959–66.
   PubMedGoogle Scholar
• Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921–9.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009;458:641–5.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Peng Y, Yan H, Xu K, Saito M, Wu H, et al. Multilayered defense in HLA-B51-associated HIV viral control. J Immunol 2011;187:684–91.
   PubMedGoogle Scholar